Related Experiment Video
Updated: Jan 9, 2026
Left Atrial Stenosis Induced Pulmonary Venous Arterialization and Group 2 Pulmonary Hypertension in Rat
Published on: November 18, 2018
Vaccination utilization in patients with pulmonary hypertension
Rodolfo A Estrada1, Hasan Baher1, Liwayway Andrade2
1Division of Pulmonary Diseases and Critical Care Medicine, UT Health San Antonio, TX, USA; Department of Medicine, South Texas Veterans Health Care System, San Antonio, TX, USA.
Vaccination rates for pulmonary hypertension (PH) patients are suboptimal, especially for influenza. Targeted interventions are needed to improve vaccine adherence in this high-risk group.
Area of Science:
- Pulmonary Hypertension Research
- Vaccinology
- Public Health
Background:
- Pulmonary hypertension (PH) is a severe condition with high morbidity and mortality.
- Vaccinations against SARS-CoV-2, pneumococcus, and influenza are recommended for PH patients.
- Real-world vaccination rates and influencing factors in PH patients are not well understood.
Purpose of the Study:
- To assess vaccination adherence in adult PH patients.
- To identify demographic and clinical factors associated with vaccination rates.
- To highlight the need for improved vaccine uptake in this vulnerable population.
Main Methods:
- Retrospective observational study of 175 adult PH patients.
- Data collected from December 2020 to February 2023.
- Analysis of vaccination status for SARS-CoV-2, pneumococcus, and influenza.
Main Results:
- SARS-CoV-2 vaccination coverage was 68%, with only 15% receiving boosters.
- Pneumococcal vaccination prevalence was 50%.
- Influenza vaccination adherence was low at 23% for the 2022-2023 season.
- Hispanic ethnicity and WHO Group 1 PH were linked to higher influenza vaccination rates.
Conclusions:
- Vaccination rates in PH patients are suboptimal, particularly for influenza.
- Current guidelines are not fully translating into adequate vaccine uptake.
- Educational strategies and policy advocacy are crucial to enhance vaccination adherence in PH patients.
Related Concept Videos
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
01:16Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
01:30Pneumonia V: Nursing management and Prevention
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed....
01:30Pulmonary Hypertension: Classification and Pathogenesis
There are various classifications for PH, each relating to different underlying causes and also...
01:28Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
01:51Vaccinations